Oncometabolomics in cancer research

References

• Kim YS, Maruvada P, Milner JA. Metabolomics in biomarker discovery: future uses for cancer prevention. Future Oncol. 4(1), 93–102 (2008).
   Google Scholar
• Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 15(2), 431–440 (2009).
   PubMed Web of Science ®Google Scholar
• O'Connell TM. Recent advances in metabolomics in oncology. Bioanalysis 4(4), 431–451 (2012).
   Google Scholar
• Nicholson JK, Lindon JC. Metabonomics. Nature 45(23), 1054–1056 (2008).
   Google Scholar
• Nordstrom A, Lewensohn R. Metabolomics: moving to the clinic. J. Neuroimmune Pharmacol. 5(1), 4–17 (2010).
   PubMed Web of Science ®Google Scholar
• Davis VW, Bathe OF, Schiller DE, Slupsky CM, Sawyer MB. Metabolomics and surgical oncology: Potential role for small molecule biomarkers. J. Surg. Oncol. 103(5), 451–459 (2011).
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang P, Yang Y, Wang F, Qin H. Metabolomics in the fields of oncology: a review of recent research. Mol. Biol. Rep. 39(7), 7505–7511 (2012).
   Google Scholar
• Patti GJ, Yanes O, Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy. Nat. Rev. Mol. Cell Biol. 13(4), 263–269 (2012).
   PubMed Web of Science ®Google Scholar
• Claudino WM, Goncalves PH, di Leo A, Philip PA, Sarkar FH. Metabolomics in cancer: a bench-to-bedside intersection. Crit. Rev. Oncol. Hematol. 84(1), 1–7 (2012).
   PubMed Web of Science ®Google Scholar
• Fiehn O. Combining genomics, metabolome analysis and biochemical modelling to understand metabolic networks. Comp. Funct. Genomics. 2, 155–168 (2001).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930), 1029–1033 (2009).
   PubMed Web of Science ®Google Scholar
• Serkova NJ, Glunde K. Metabolomics of Cancer. In: Methods in Molecular Biology, Tumor Biomarker Discovery. Tainsky MA (Ed.). Humana Press, NY, USA, 273–295 (2009).
   Google Scholar
• Fernie AR, Trethewey RN, Krotzky AJ, Willmitzer L. Metabolite profiling: from diagnostics to systems biology. Nat. Rev. Mol. Cell Biol. 5(9), 763–769 (2004).
   PubMed Web of Science ®Google Scholar
• Beckonert O, Coen M, Keun HC et al. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat. Protoc. 5(6), 1019–1032 (2010).
   PubMed Web of Science ®Google Scholar
• Johnson CH, Gonzalez FJ. Challenges and opportunities of metabolomics. J. Cell. Physiol. 227(8), 2975–2981 (2012).
   PubMed Web of Science ®Google Scholar
• Becker S, Kortz L, Helmschrodt C, Thiery J, Ceglarek U. LC-MS-based metabolomics in the clinical laboratory. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 883–884, 68–75 (2012).
   Google Scholar
• Fan TW, Lorkiewicz PK, Sellers K, Moseley HN, Higashi RM, Lane AN. Stable isotope-resolved metabolomics and applications for drug development. Pharmacol. Ther. 133(3), 366–391 (2012).
   Web of Science ®Google Scholar
• Vaughan AA, Dunn WB, Allwood JW et al. Liquid chromatography-mass spectrometry calibration transfer and metabolomics data fusion. Anal. Chem. 84(22), 9848–9857 (2012).
   PubMedGoogle Scholar
• Kamleh MA, Ebbels TM, Spagou K, Masson P, Want EJ. Optimizing the use of quality control samples for signal drift correction in large-scale urine metabolic profiling studies. Anal. Chem. 84(6), 2670–2677 (2012).
   Google Scholar
• Benton HP, Want E, Keun HC et al. Intra- and interlaboratory reproducibility of ultra performance liquid chromatography-time-of-flight mass spectrometry for urinary metabolic profiling. Anal. Chem. 84(5), 2424–2432 (2012).
   PubMed Web of Science ®Google Scholar
• Kelly AD, Breitkopf SB, Yuan M, Goldsmith J, Spentzos D, Asara JM. Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma. PLoS ONE 6(10), e25357 (2011).
   Google Scholar
• Want EJ, Masson P, Michopoulos F et al. Global metabolic profiling of animal and human tissues via UPLC-MS. Nat. Protoc. 8(1), 17–32 (2013).
   PubMed Web of Science ®Google Scholar
• Serkova NJ, Brown MS. Quantitative analysis in magnetic resonance spectroscopy: from metabolic profiling to in vivo biomarkers. Bioanalysis 4(3), 321–341 (2012).
   PubMed Web of Science ®Google Scholar
• Bathen TF, Sitter B, Sjobakk TE, Tessem MB, Gribbestad IS. Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res. 70(17), 6692–6696 (2010).
   PubMedGoogle Scholar
• Serkova NJ, Niemann CU. Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics. Expert Rev. Mol. Diagn. 6(5), 717–731 (2006).
   PubMed Web of Science ®Google Scholar
• Wong A, Jimenez B, Li X et al. Evaluation of high resolution magic-angle coil spinning NMR spectroscopy for metabolic profiling of nanoliter tissue biopsies. Anal. Chem. 84(8), 3843–3848 (2012).
   Google Scholar
• Glunde K, Jiang L, Moestue SA, Gribbestad IS. MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR Biomed. 24(6), 673–690 (2011).
   PubMed Web of Science ®Google Scholar
• Benjamin DI, Cravatt BF, Nomura DK. Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell. Metab. 16(5), 565–577 (2012).
   PubMedGoogle Scholar
• Chaudhri VK, Salzler GG, Dick SA et al. Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor. Mol. Cancer Res. 11(6), 579–592 (2013).
   PubMedGoogle Scholar
• Teicher BA, Linehan WM, Helman LJ. Targeting cancer metabolism. Clin. Cancer Res. 18(20), 5537–5545 (2012).
   PubMed Web of Science ®Google Scholar
• Zhao Y, Liu H, Riker AI et al. Emerging metabolic targets in cancer therapy. Front. Biosci. 16, 1844–1860 (2011).
   Web of Science ®Google Scholar
• Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 4, e532 (2013).
   PubMed Web of Science ®Google Scholar
• Davis VW, Schiller DE, Eurich D, Bathe OF, Sawyer MB. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Ann. Surg. Oncol. (2012).
   Google Scholar
• Huang J, Sun J, Chen Y et al. Analysis of multiplex endogenous estrogen metabolites in human urine using ultra-fast liquid chromatography-tandem mass spectrometry: a case study for breast cancer. Anal. Chim. Acta 711, 60–68 (2012).
   Google Scholar
• Chinnaiyan P, Kensicki E, Bloom G et al. The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res. 72(22), 5878–5888 (2012).
   PubMed Web of Science ®Google Scholar
• Reitman ZJ, Jin G, Karoly ED et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl Acad. Sci. USA. 108(8), 3270–3275 (2011).
   PubMed Web of Science ®Google Scholar
• Budhu A, Roessler S, Zhao X et al. Integrated Metabolite and Gene Expression Profiles Identify Lipid Biomarkers Associated With Progression of Hepatocellular Carcinoma and patient outcomes. Gastroenterology 144(5), 1066–1075 (2013).
   PubMed Web of Science ®Google Scholar
• Ressom HW, Xiao JF, Tuli L et al. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal. Chim. Acta 743, 90–100 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang A, Sun H, Yan G, Han Y, Ye Y, Wang X. Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. Clin. Chim. Acta 418, 86–90 (2013).
   PubMed Web of Science ®Google Scholar
• Zhang J, Bowers J, Liu L et al. Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. PLoS ONE 7(1), e30181 (2012).
   PubMed Web of Science ®Google Scholar
• Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231), 910–914 (2009).
   PubMed Web of Science ®Google Scholar
• Jentzmik F, Stephan C, Lein M et al. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J. Urol. 185(2), 706–711 (2011).
   Google Scholar
• Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun. Mass Spectrom. 24(5), 613–620 (2010).
   PubMed Web of Science ®Google Scholar
• Bathe OF, Shaykhutdinov R, Kopciuk K et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol. Biomarkers Prev. 20(1), 140–147 (2011).
   PubMed Web of Science ®Google Scholar
• OuYang D, Xu J, Huang H, Chen Z. Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis. Appl. Biochem. Biotechnol. 165(1), 148–154 (2011).
   PubMed Web of Science ®Google Scholar
• Napoli C, Sperandio N, Lawlor RT, Scarpa A, Molinari H, Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. J. Proteome Res. 11(2), 1274–1283 (2012).
   Google Scholar
• Zhang L, Jin H, Guo X et al. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by (1)H nuclear magnetic resonance-based metabonomic profiles. Clin. Biochem. 45(13–14), 1064–1069 (2012).
   PubMed Web of Science ®Google Scholar
• Cheng Y, Xie G, Chen T et al. Distinct urinary metabolic profile of human colorectal cancer. J. Proteome Res. 11(2), 1354–1363 (2012).
   PubMed Web of Science ®Google Scholar
• Chen JL, Fan J, Yan LS et al. Urine metabolite profiling of human colorectal cancer by capillary electrophoresis mass spectrometry based on MRB. Gastroenterol. Res. Pract. 2012, 8 (2012).
   Google Scholar
• Hasim A, Ma H, Mamtimin B et al. Revealing the metabonomic variation of EC using (1)H-NMR spectroscopy and its association with the clinicopathological characteristics. Mol. Biol. Rep. 39(9), 8955–8964 (2012).
   PubMed Web of Science ®Google Scholar
• Davis VW, Schiller DE, Eurich D, Sawyer MB. Urinary metabolomic signature of esophageal cancer and Barrett's esophagus. World J. Surg. Oncol. 10, 271 (2012).
   PubMedGoogle Scholar
• Zhou M, Guan W, Walker LD et al. Rapid mass spectrometric metabolic profiling of blood sera detects ovarian cancer with high accuracy. Cancer Epidemiol. Biomarkers Prev. 19(9), 2262–2271 (2010).
   Google Scholar
• Silva EG, Lopez PR, Atkinson EN, Fente CA. A new approach for identifying patients with ovarian epithelial neoplasms based on high-resolution mass spectrometry. Am. J. Clin. Pathol. 134(6), 903–909 (2010).
   Google Scholar
• Huang Z, Lin L, Gao Y et al. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach. Mol. Cell Proteomics. 10(10), M111.007922 (2011).
   PubMedGoogle Scholar
• Selnaes KM, Gribbestad IS, Bertilsson H et al. Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer - investigation of a correlation with Gleason score. NMR Biomed. 26(5), 600–606 (2012).
   Google Scholar
• Asiago VM, Alvarado LZ, Shanaiah N et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 70(21), 8309–8318 (2010).
   PubMed Web of Science ®Google Scholar
• Keun HC, Sidhu J, Pchejetski D et al. Serum molecular signatures of weight change during early breast cancer chemotherapy. Clin. Cancer Res. 15(21), 6716–6723 (2009).
   Google Scholar
• Cho SH, Choi MH, Lee WY, Chung BC. Evaluation of urinary nucleosides in breast cancer patients before and after tumor removal. Clin. Biochem. 42(6), 540–543 (2009).
   PubMed Web of Science ®Google Scholar
• Cao MD, Sitter B, Bathen TF et al. Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR Biomed. 25(2), 369–378 (2012).
   Google Scholar
• Wei S, Liu L, Zhang J et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol. Oncol. 7(3), 297–307 (2012).
   Google Scholar
• Astrakas L, Blekas KD, Constantinou C et al. Combining magnetic resonance spectroscopy and molecular genomics offers better accuracy in brain tumor typing and prediction of survival than either methodology alone. Int. J. Oncol. 38(4), 1113–1127 (2011).
   Google Scholar
• Weaver Z, Difilippantonio S, Carretero J et al. Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. Cancer Res. 72(22), 5921–5933 (2012).
   Google Scholar
• Ohmine K, Kawaguchi K, Ohtsuki S et al. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells. Pharm. Res. 29(7), 2006–2016 (2012).
   Google Scholar
• Tripathi P, Kamarajan P, Somashekar BS et al. Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target. Int. J. Biochem. Cell Biol. 44(11), 1852–1861 (2012).
   PubMed Web of Science ®Google Scholar
• Cheng HH, Kuo CC, Yan JL et al. Control of cyclooxygenase-2 expression and tumorigenesis by endogenous 5-methoxytryptophan. Proc. Natl Acad. Sci. U. S. A. 109(33), 13231–13236 (2012).
   Google Scholar
• Jain M, Nilsson R, Sharma S et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336(6084), 1040–1044 (2012).
   PubMed Web of Science ®Google Scholar
• Tiziani S, Kang Y, Choi JS, Roberts W, Paternostro G. Metabolomic high-content nuclear magnetic resonance-based drug screening of a kinase inhibitor library. Nat. Commun. 2, 545 (2011).
   Google Scholar
• Griffin JL, Kauppinen RA. Tumour metabolomics in animal models of human cancer. J. Proteome Res. 6(2), 498–505 (2007).
   PubMed Web of Science ®Google Scholar